These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1454 related items for PubMed ID: 22440513

  • 1. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
    Dempster DW, Lambing CL, Kostenuik PJ, Grauer A.
    Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
    [Abstract] [Full Text] [Related]

  • 2. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM, Iranikhah MM, Wilborn TW.
    Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys.
    Ominsky MS, Stouch B, Schroeder J, Pyrah I, Stolina M, Smith SY, Kostenuik PJ.
    Bone; 2011 Aug; 49(2):162-73. PubMed ID: 21497676
    [Abstract] [Full Text] [Related]

  • 5. Clinical use of denosumab for the treatment for postmenopausal osteoporosis.
    Lewiecki EM.
    Curr Med Res Opin; 2010 Dec; 26(12):2807-12. PubMed ID: 21050058
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Denosumab. The first inhibitor of RANK-ligand for treatment of osteoporosis].
    Bruhn C.
    Med Monatsschr Pharm; 2010 Oct; 33(10):370-5. PubMed ID: 21072910
    [Abstract] [Full Text] [Related]

  • 8. Denosumab for the reduction of bone loss in postmenopausal osteoporosis: a review.
    Bridgeman MB, Pathak R.
    Clin Ther; 2011 Nov; 33(11):1547-59. PubMed ID: 22108301
    [Abstract] [Full Text] [Related]

  • 9. Denosumab in postmenopausal women with low bone mineral density.
    McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ, AMG 162 Bone Loss Study Group.
    N Engl J Med; 2006 Feb 23; 354(8):821-31. PubMed ID: 16495394
    [Abstract] [Full Text] [Related]

  • 10. Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases.
    Delmas PD.
    J Clin Densitom; 2008 Feb 23; 11(2):325-38. PubMed ID: 18375161
    [Abstract] [Full Text] [Related]

  • 11. Denosumab update.
    Lewiecki EM.
    Curr Opin Rheumatol; 2009 Jul 23; 21(4):369-73. PubMed ID: 19424068
    [Abstract] [Full Text] [Related]

  • 12. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.
    Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, Sun N, Chen C, Li L, Cattley RC, Van G, Scully S, Elliott R, Grisanti M, Morony S, Tan HL, Asuncion F, Li X, Ominsky MS, Stolina M, Dwyer D, Dougall WC, Hawkins N, Boyle WJ, Simonet WS, Sullivan JK.
    J Bone Miner Res; 2009 Feb 23; 24(2):182-95. PubMed ID: 19016581
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
    Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y, Wang A, Siddhanti S, Fitzpatrick LA, AMG 162 Bone Loss Study Group.
    J Bone Miner Res; 2007 Dec 23; 22(12):1832-41. PubMed ID: 17708711
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Denosumab and bisphosphonates: different mechanisms of action and effects.
    Baron R, Ferrari S, Russell RG.
    Bone; 2011 Apr 01; 48(4):677-92. PubMed ID: 21145999
    [Abstract] [Full Text] [Related]

  • 17. Denosumab, a RANK ligand inhibitor, for postmenopausal women with osteoporosis.
    Sutton EE, Riche DM.
    Ann Pharmacother; 2012 Apr 01; 46(7-8):1000-9. PubMed ID: 22837347
    [Abstract] [Full Text] [Related]

  • 18. Denosumab--an emerging treatment for postmenopausal osteoporosis.
    Lewiecki EM.
    Expert Opin Biol Ther; 2010 Mar 01; 10(3):467-76. PubMed ID: 20095877
    [Abstract] [Full Text] [Related]

  • 19. [Denosumab for treatment of postmenopausal osteoporosis].
    Syversen U, Halse JI, Geisler J, Eriksen EF.
    Tidsskr Nor Laegeforen; 2011 Oct 04; 131(19):1893-6. PubMed ID: 21984295
    [Abstract] [Full Text] [Related]

  • 20. Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody.
    Kostenuik PJ, Smith SY, Jolette J, Schroeder J, Pyrah I, Ominsky MS.
    Bone; 2011 Aug 04; 49(2):151-61. PubMed ID: 21457806
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 73.